Back to Newsroom

Ocata Therapeutics Receives Important New U.S. Patent for its RPE Therapy for Macular Degenerative Diseases

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that it continues to fortify the scope of protection covering its retinal pigment epithelium (RPE) transplant technology with the issuance by the United States Patent and Trademark Office (USPTO) of U.S. Patent No 9,045,732. This new patent further strengthens the Company’s comprehensive suite of intellectual property which the Company believes to be an important component of its sustainable competitive advantage in Regenerative Ophthalmology.

Click here to read more